Hypothesis

Selective metabolic restoration of G1-arrested, TGF‑β–secreting senescent fibroblasts via nanoliposomal resveratrol enhances SIRT1‑lamin A activity, reinforcing their matrix‑supportive SASP and preventing fibrosis, whereas broad senolytic ablation of these cells exacerbates extracellular‑matrix dysregulation.

Rationale

Recent work shows senescent cells are functionally heterogeneous: G2‑arrested cells secrete high IL‑6 and are ABT263‑sensitive, while G1‑arrested cells tend to produce a TGF‑β/collagen‑rich secretome that supports tissue repair [1] [2]. NOTCH1‑induced senescence in fibroblasts exemplifies this, generating a SASP rich in TGF‑β and collagen that counters the IL‑6/IL‑8 inflammatory cascade typical of oncogene‑induced senescence [2]. Importantly, SIRT1 activity is compromised in aging because its interaction with lamin A is weakened; resveratrol can indirectly boost SIRT1 by stabilizing this interaction [4] but suffers from poor bioavailability [5]. Nanoliposomal encapsulation overcomes this limitation, improving stability and controlled release [6].

We propose that nanoliposomal resveratrol will preferentially rescue the SIRT1‑lamin A axis in G1‑arrested, TGF‑β–secreting senescent fibroblasts, thereby:

1. Amplifying their matrix‑protective SASP (↑ TGF‑β, ↑ collagen I/III, ↓ IL‑6/IL‑8).
2. Enhancing autocrine SIRT1 signaling, which reinforces lamin A stability and promotes a chromatin state that limits pro‑fibrotic gene expression.
3. Preserving the senescent cell population (no significant drop in p16^INK4a^ or SA‑β‑gal^+^ cells) while improving tissue mechanics.

In contrast, senolytic agents such as ABT263 will indiscriminately eliminate both G1‑ and G2‑arrested senescent cells, leading to loss of TGF‑β‑rich stromal support, unchecked fibroblast activation, and exacerbated collagen cross‑linking—hallmarks of pathological fibrosis.

Novel Mechanistic Insight

Beyond SIRT1 activation, we hypothesize that rescued lamin A‑SIRT1 complexes increase nuclear mechanotransduction signaling. Stabilized lamin A alters nuclear stiffness, reducing YAP/TAZ nuclear translocation in senescent fibroblasts. Lower YAP/TAZ activity diminishes transcription of CTGF and α‑SMA, curbing the myofibroblast shift that drives fibrosis. This creates a feedback loop where metabolic reprogramming (SIRT1) reinforces nuclear mechanical signaling (lamin A–YAP/TAZ) to keep senescent fibroblasts in a reparative, non‑contractile state.

Experimental Plan (Testable & Falsifiable)

Model: Injured dermal wound or CCl_4‑induced liver fibrosis in aged (20‑month) mice. Groups:

1. Vehicle control.
2. Nanoliposomal resveratrol (dose achieving ~5‑fold increased plasma AUC vs free resveratrol).
3. ABT263 (standard senolytic dose).
4. Nanoliposomal resveratrol + ABT263 (to test whether rescue overrides clearance).

Readouts (at 7 and 14 days post‑treatment):

• Flow cytometry for p16^INK4a^ and SA‑β‑gal to quantify senescent fibroblast frequency.
• Immunofluorescence for lamin A, SIRT1, and acetyl‑p53 (SIRT1 activity readout) in p16^+^ cells.
• Secretome profiling (Luminex) of isolated senescent fibroblasts for TGF‑β, IL‑6, IL‑8, collagen‑I.
• Nuclear YAP/TAZ localization (immunostaining) and downstream targets (CTGF, α‑SMA) via qPCR.
• Biochemical assays: hydroxyproline content (collagen deposition), second‑harmonic generation imaging for collagen cross‑linking.
• Functional outcomes: wound closure rate, liver fibrosis score (Sirius Red).

Predicted Outcomes Supporting the Hypothesis:

• Nanoliposomal resveratrol increases SIRT1‑lamin A interaction and reduces p53 acetylation in p16^+^ fibroblasts without decreasing their abundance.
• TGF‑β secretion rises, IL‑6/IL‑8 falls, and collagen deposition improves, correlating with enhanced wound closure or reduced fibrosis.
• YAP/TAZ remains cytoplasmic in senescent fibroblasts, accompanied by ↓ CTGF/α‑SMA.
• ABT263 reduces p16^+^ cells but leads to ↑ YAP/TAZ nuclear signaling, ↑ α‑SMA, and worsened fibrosis.
• Combined treatment shows that nanoliposomal resveratrol can mitigate the fibrotic exacerbation caused by ABT263 if administered prior to senolytic clearance.

Falsification Criteria: If nanoliposomal resveratrol fails to increase SIRT1‑lamin A activity in G1‑arrested senescent fibroblasts or does not improve matrix deposition/YAP/TAZ localization despite increased drug exposure, the hypothesis is refuted. Likewise, if senolytic ablation does not worsen fibrosis or if clearing senescent cells improves outcomes independent of their SASP phenotype, the proposed protective role of G1‑arrested, TGF‑β–secreting senescent fibroblasts would be invalidated.

Implications

Validating this hypothesis would shift the senotherapeutic paradigm from blanket elimination to precision metabolic reprogramming, preserving the "chaperone" senescent subsets that sustain tissue architecture while neutralizing deleterious phenotypes. It also provides a mechanistic bridge between nutraceutical delivery, nuclear mechanobiology, and fibrosis prevention—offering a translational avenue for age‑related regenerative medicine.